A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Croop R, Berman G, Kudrow D, Mullin K, et al. Cephalalgia 2024;44:3331024241232944.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Croop R, Berman G, Kudrow D, Mullin K, et al. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia 2024;44:3331024241232944.
PMID: 38659334